Treatment of severe sepsis with Xigris: implications for the clinical nurse specialist.
Powers
Jan
J
Clarian Health Partners, Methodist Hospital, Indianapolis, Indiana, USA. jpowers@clarian.org
Jacobi
Judith
J
D000890:Anti-Infective Agents / Q000494:pharmacology / Q000627:therapeutic use*; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000494:pharmacology / Q000627:therapeutic use*; D003422:Critical Care; D005343:Fibrinolytic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D005544:Forecasting; D006801:Humans; D009720:Nurse Clinicians; D024802:Nurse's Role; D018579:Patient Selection; D011486:Protein C / Q000494:pharmacology / Q000627:therapeutic use*; D011994:Recombinant Proteins / Q000494:pharmacology / Q000627:therapeutic use*; D018805:Sepsis / Q000188:drug therapy* / Q000451:nursing; D018746:Systemic Inflammatory Response Syndrome / Q000188:drug therapy* / Q000451:nursing; D016896:Treatment Outcome
D000890:Anti-Infective Agents; D000894:Anti-Inflammatory Agents, Non-Steroidal; D005343:Fibrinolytic Agents; D011486:Protein C; D011994:Recombinant Proteins; C421124:drotrecogin alfa activated